-

Ribon Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria Richon, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held November 30 – December 3, 2020.

About Ribon Therapeutics

Ribon Therapeutics is a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. We are exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD+-utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Our lead program is RBN-2397, a first-in-class PARP7 inhibitor in clinical development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts. For more information visit www.RibonTx.com.

Contacts

Brendan Burns
Argot Partners
212.600.1902
Ribon@argotpartners.com

Industry:

Ribon Therapeutics

Release Versions
English

Contacts

Brendan Burns
Argot Partners
212.600.1902
Ribon@argotpartners.com

More News From Ribon Therapeutics

Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Severe Atopic Dermatitis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical-stage biotechnology company developing therapeutics to target stress support pathways, today announced dosing the first patient in the open-label cohort of patients with moderate-to-severe atopic dermatitis to measure the pharmacodynamic activity of RBN-3143 and evaluate the safety and preliminary efficacy of 28 days of administration of RBN-3143 in this target population. “As a first-in-class, oral, small molecule inhibitor of P...

Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical-stage biotechnology company developing therapeutics to target stress support pathways, today announced a $25 million investment from Pfizer. Ribon plans to use the proceeds to support clinical development of its potentially first-in-class oral small molecule programs in oncology (RBN-2397, a PARP7 inhibitor) and immunology (RBN-3143, a PARP14 inhibitor). As part of the investment, Robert Rickert, Ph.D., Senior Vice President and...

Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the acquisition of its CD38 program with Boehringer Ingelheim. This includes a small molecule inhibitor designed to modulate intra- and extracellular CD38 activity, potentially restoring immune function in various diseases, as well as corresponding patents and other proprietary information. B...
Back to Newsroom